Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marla C Dubinsky

Showing results (221-230 of 286) with videos related to

Pageof 29
Sort By:
BMJ Open Gastroenterology|January 8, 2025
Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitisSéverine Vermeire, David T Rubin, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases|September 7, 2006
Challenges in pediatric inflammatory bowel diseaseAthos Bousvaros, Francisco Sylvester, Subra Kugathasan, et al.
Journal of Pediatric Gastroenterology and Nutrition|April 27, 2007
Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America, , Athos Bousvaros, et al.
Inflammatory Bowel Diseases|May 20, 2022
High Prevalence of Malnutrition and Micronutrient Deficiencies in Patients With Inflammatory Bowel Disease Early in Disease CourseStephanie L Gold, Loren G Rabinowitz, Laura Manning, et al.
Journal of Crohn'S & Colitis|May 18, 2025
Distinct perturbances in metabolic pathways associate with disease progression in inflammatory bowel diseaseArno R Bourgonje, Susanne Ibing, Alexandra E Livanos, et al.
The American Journal of Gastroenterology|May 7, 2019
Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricturing Complications in Pediatric Crohn's DiseaseJing Wu, David M Lubman, Subra Kugathasan, et al.
Journal of Crohn'S & Colitis|April 13, 2024
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical ProgrammeLaurent Peyrin-Biroulet, Marla C Dubinsky, Bruce E Sands, et al.
Inflammatory Bowel Diseases|August 22, 2020
Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United StatesBenjamin L Cohen, Zane R Gallinger, Christina Ha, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 5, 2025
Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction TreatmentRemo Panaccione, Marc Ferrante, Iris Dotan, et al.
Inflammatory Bowel Diseases|October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Pageof 29

Showing results (221-230 of 286) with videos related to

Sort By:
Pageof 29
BMJ Open Gastroenterology|January 8, 2025
Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitisSéverine Vermeire, David T Rubin, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases|September 7, 2006
Challenges in pediatric inflammatory bowel diseaseAthos Bousvaros, Francisco Sylvester, Subra Kugathasan, et al.
Journal of Pediatric Gastroenterology and Nutrition|April 27, 2007
Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America, , Athos Bousvaros, et al.
Inflammatory Bowel Diseases|May 20, 2022
High Prevalence of Malnutrition and Micronutrient Deficiencies in Patients With Inflammatory Bowel Disease Early in Disease CourseStephanie L Gold, Loren G Rabinowitz, Laura Manning, et al.
Journal of Crohn'S & Colitis|May 18, 2025
Distinct perturbances in metabolic pathways associate with disease progression in inflammatory bowel diseaseArno R Bourgonje, Susanne Ibing, Alexandra E Livanos, et al.
The American Journal of Gastroenterology|May 7, 2019
Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricturing Complications in Pediatric Crohn's DiseaseJing Wu, David M Lubman, Subra Kugathasan, et al.
Journal of Crohn'S & Colitis|April 13, 2024
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical ProgrammeLaurent Peyrin-Biroulet, Marla C Dubinsky, Bruce E Sands, et al.
Inflammatory Bowel Diseases|August 22, 2020
Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United StatesBenjamin L Cohen, Zane R Gallinger, Christina Ha, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 5, 2025
Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction TreatmentRemo Panaccione, Marc Ferrante, Iris Dotan, et al.
Inflammatory Bowel Diseases|October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Pageof 29